Table 1 Demographics, clinical manifestations and laboratory findings of patients with Guillain-Barré syndrome (GBS)
Basic information | |
|---|---|
Male/female ratio | 311/212 |
Age (years), median (IQR) | 36 (26–45) |
Duration in hospital (days), median (IQR) | 15 (10–20) |
Symptoms of antecedent infection (n = 523) | |
Interval between infection and onset (days), median (IQR) | 5 (2–9) |
Diarrhea, No. (%) | 137 (26.20) |
Upper respiratory tract infection, No. (%) | 153 (29.25) |
Severity of disease (n = 523) | |
MRC sum score at admission, median (IQR) | 48 (42–56) |
HFGS at admission, median (IQR) | 3 (2–4) |
MRC sum score at nadir, median(IQR) | 48 (36–54) |
HFGS at nadir, median (IQR) | 3 (2–4) |
Interval between onset and nadir (days), median (IQR) | 8 (6–12) |
MRC sum score at discharge, median (IQR) | 56 (49–60) |
HFGS at discharge, median(IQR) | 2 (1–3) |
Clinical manifestations (n = 523) | |
Cranial nerve involvement, No. (%) | 236 (45.12) |
Hyporeflexia/areflexia, No. (%) | 484 (92.54) |
Superficial sensation deficits, No. (%) | 223 (43.05) |
Autonomic deficits, No. (%) | 289 (55.26) |
Dyspnea, No. (%) | 134 (25.62) |
Ventilator dependence, No. (%) | 64 (12.24) |
Blood routine examination at admission (n = 523) | |
White blood cell, mean (SD), 109/L | 9.00 (3.61) |
Neutrophil, mean (SD), % | 68.75 (3.63) |
Lymphocyte, mean (SD), % | 23.36 (0.10) |
Lumbar puncture (n = 287) | |
Protein concentration, mean (SD), g/L | 1.05 (0.88) |
White blood cell, mean (SD), 106/L | 3 (2–7) |
Albumin-cytologic dissociations, No. (%) | 192 (66.90) |
IgG concentration, mean (SD), mg/L | 189.24 (205.63) |
Nerve conduction studies (n = 165) | |
Demyelinating group, No. (%) | 89 (53.94) |
Axonal group, No. (%) | 46 (27.88) |
Overlap group, No. (%) | 30 (18.18) |